SCHEMBL560593

SCHEMBL560593

Cc1ccc2nc(-c3nc(C(=O)Nc4ccccc4)cnc3N)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 5/20 0.58
MMP9 P14780 5/20 0.58
MMP8 P22894 5/20 0.58
MMP13 P45452 4/20 0.58
CNR1 P21554 2/20 0.53
ATR Q13535 6/20 0.51
HPSE Q9Y251 1/20 0.50
KDM4E B2RXH2 3/20 0.49
NPC1 O15118 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 3/20 0.49
RAB9A P51151 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
POLB P06746 2/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559719 0.91 RAB9A (0.48) MMP2MMP9MMP8MMP13ATR
SCHEMBL560651 0.85 ATR (0.53) MMP2MMP9MMP8MMP13ATR
SCHEMBL560697 0.85 ATR (0.48) MMP2MMP9MMP8MMP13CNR1
SCHEMBL560932 0.85 ATR (0.48) MMP2MMP9MMP8MMP13CNR1
SCHEMBL560599 0.84 MMP2 (0.61) MMP2MMP9MMP8MMP13CNR1
SCHEMBL560242 0.82 ATR (0.51) MMP2MMP9MMP8MMP13ATR
SCHEMBL560937 0.82 ATR (0.55) ATRHPSEKDM4ENPC1ALDH1A1
SCHEMBL560220 0.82 ATR (0.53) MMP2MMP9MMP8MMP13ATR
SCHEMBL10166538 0.82 ATR (0.57) MMP2MMP9MMP8CNR1ATR
SCHEMBL560124 0.81 ATR (0.52) MMP2MMP9MMP8MMP13ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 MMP2 4673/4885MMP9 4711/4885MMP8 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.